title: [Therapeutic options for haemangiomas of infancy].
abstract: The necessity of haemangioma treatment in infants has been controversially discussed for years. One reason is the favoured clinical observation of a potential spontaneous involution without any therapeutic approach or medical treatment, thus avoiding their specific risks. On the other hand, there are several reports on serious cases with -rapidly growing haemangiomas including severe consequences. There are potential complications such as loss of visus in cases of periorbital manifestation. A basic problem is the lack of a unique systematic classification, on the basis of which -diagnostic measures, therapeutic indications and modes could be compared. Such a classification would be much more competent including a sufficient comparison of treatment results. The basic aim in management is to achieve control of the haemangioma growth and induction of its sub-sequent involution back to only a cosmetic detraction. Each threatening functional loss can be classified as an urgent indication for treatment. There is a need to consider the treatment options and their values; in particular, cryotherapy or laser therapy in localised manifestations are mostly -favoured because of the convincing evidence from available data. In the case of a more disseminated haemangioma manifestation, the initiation of propranol medication is possible, a novel drug for this indication. However, there are no follow-up data on the mid-term or long-term outcome available at this time. Further studies on the subject are therefore required.
authors.affiliation: Universitätsklinikum Magdeburg, Arbeitsbereich Kinderchirurgie, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Magdeburg, Deutschland. hardy.krause@med.ovgu.de
authors.forename: H
authors.initials: H
authors.lastname: Krause
authors.forename: H-J
authors.initials: HJ
authors.lastname: Haß
authors.forename: S
authors.initials: S
authors.lastname: Kroker
authors.forename: F
authors.initials: F
authors.lastname: Meyer
authors.forename: Z
authors.initials: Z
authors.lastname: Halloul
authors.forename: W
authors.initials: W
authors.lastname: Wagemann
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017679:Cryotherapy; D006391:Hemangioma / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D053685:Laser Therapy; D009365:Neoplasm Regression, Spontaneous; D011433:Propranolol / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000145:classification / Q000175:diagnosis / Q000628:therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol